Two small peptide sequences for binding to multiple serotypes of adenovirus and their applications
By developing VX and D05 small peptide sequences for the manufacture of alkali-resistant affinity chromatography media ligands, the problem of insufficient purification ability of multiple serotypes of AAV virus vectors is solved, and efficient and economical purification effects are achieved, reducing gene therapy The cost and improves the alkali resistance of the purification medium.
Patent Information
- Application Number
- CN202410778851.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-17
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-06-17
AI Technical Summary
In the prior art, the purification process platform of AAV virus vector lacks the challenge of effective and amplification, especially the purification capacity of various serotype AAV viruses is insufficient, resulting in high production costs and impermissible alkali resistance and inability to reuse, which limits the The economy and efficiency of gene therapy.
Two small peptide sequences, VX small peptide sequence and D05 small peptide sequence were developed to make alkali-resistant affinity chromatography media ligands, which can bind to a variety of serotype AAV viruses, have high affinity, and are suitable for a variety of Purification of AAV virus particles or vectors.
It has achieved efficient purification of various serotype AAV viruses, reduced production costs, improved alkali resistance and reusability of purification media, and enhanced the economic and efficiency of gene therapy.
Smart Images

Figure CN118530345B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to two small peptide sequences for binding to multiple serotypes of adenoviruses and applications thereof. Background Art
[0002] In recent years, cell and gene therapy drugs have developed rapidly, and a considerable number of drugs have entered the clinical trial stage. Many of them use AAV viral vectors to deliver target genes to target cells or tissues and organs. It involves the treatment of a variety of genetic diseases, such as cystic fibrosis, hemophilia, etc. In addition, they are also used to treat certain cancers and neurological diseases, such as Parkinson's disease and Huntington's disease. These trials involved patients of different age groups and achieved initial success. They showed good safety and efficacy in clinical trials. AAV viral vectors are generally considered to be a very suitable viral vector for gene therapy because they exist naturally in the human body and induce low immune responses.
[0003] Although gene therapy medical results based on adeno-associated virus have been widely reported, the application of potential therapeutic viral vectors is currently limited by manufacturing challenges, including the lack of efficient and scalable purification process platforms. Affinity chromatography has been shown to be feasible for viral vector purification, and to date, a small number of affinity fillers for certain subtypes already exist. The earliest generation of affinity chromatography was heparin affinity chromatography. The disadvantages are high binding background, animal origin (camelid-derived ligands), and limited to certain AAV serotypes (mainly AAV2). Sulfated cellulose, CellufineTM sulphated cellulose, is an alternative material to heparin resin, with similar affinity. AVB Sepharose High Performance is a star product in affinity chromatography in recent years. It can purify a variety of AAV serotypes, AAV variants and synthetic capsids. It has strong vector binding ability, acceptable concentration and high recovery rate, and has been widely used in commercial production. The affinity of AVB to AAV varies depending on the serotype. For example, AVB has a strong affinity to AAV3, but a weak affinity to AAV8 and AAV9. The reason for the difference is whether there is an AVB binding epitope with the sequence SPAKFA in the variable region of the AAV capsid. In addition to the AVB affinity column, POROS CaptureSelect Affinity resin has also received increasing attention. This resin not only has a strong AAV particle binding capacity (approximately 10 per ml of resin binds 14vg), can also be used for the purification of AAV8 and AAV9, and the recovery rate is relatively high (AAV8 ~ 80%, AAV9 ~ 73%). POROS resin has a high purification efficiency and can effectively reduce impurities in one purification; it can be used for large-scale AAV purification when combined with chromatography equipment (Mario Mietzsch et al., Characterization of AAV-Specific Affinity Ligands: Consequences for Vector Purification and Development Strategies. DOI: 10.1016 / j.omtm.2020.10.001). Interestingly, POROS resin does not bind to AAV by "specific sequence" like ABV resin. For example, AAVrh8R is more similar to AAV9, but it can only be purified with POROSAAV8 resin; while AAV-DJ is largely homologous to AAV8, AAV-DJ cannot be purified with POROS AAV8 resin. Therefore, when using the POROS system to purify a specific AAV, it must be tested. POROS Capture Select TM The system has also developed AAVX affinity resin. POROS AAVX can be used for a wide range of serotypes, including AAV1-8, AAVrh10, and some other synthetic serotypes (Jihad El Andari and Dirk Grimm, Production, Processing, and Characterization of Synthetic AAV Gene Therapy Vectors. DOI: 10.1002 / biot.202000025). However, a big problem with this type of affinity resin is that it is not alkali-resistant, so the affinity chromatography column of the AAV viral vector becomes "disposable", which greatly increases the production cost of the AAV viral vector.
[0004] Repligen has developed -AAV series affinity fillers can achieve one-step purification of AAV-2, AAV-8 or AAV-9 viral vectors, and can be regenerated by online alkaline cleaning to improve process economy. 50μm cross-linked agarose-based balls ensure compatibility with standard bioprocess chromatography columns and flow rates (3bar@300cm / hr). It is understood that the ligands used in Repligen's AVIPure series affinity fillers are modified small peptide ligands. The only drawback is that Repligen's AVIPure series affinity fillers can only purify a certain serotype and have poor broad-spectrum properties. The reason for this situation is that the small peptides do not have a broad-spectrum property at the position where they bind to AAV.
[0005] In order to minimize the cost of gene therapy based on AAV viral vectors, the ability to purify multiple serotypes of viruses using one resin is crucial, and it is best to have a certain degree of alkaline resistance (tolerance to cleaning with NaOH solution) so that such chromatography media can be reused to further reduce costs. Therefore, screening and developing a small peptide that can bind to multiple serotypes of AAV viral vectors is crucial to achieving the above goals. Summary of the invention
[0006] Biological products (pharmaceuticals) such as AAV viral vectors for gene therapy are expensive, and their quality is strictly reviewed and regulated to ensure their effectiveness and safety. Therefore, low-cost, high-efficiency purification methods are particularly important for the life cycle of biological products (pharmaceuticals). The purpose of the present invention is to provide two small peptide sequences for binding to multiple serotypes of adenovirus, VX small peptide sequence and D05 small peptide sequence. The two small peptide sequences can be used to manufacture AAV affinity chromatography medium ligands; used to bind to multiple different serotypes of adenovirus; have strong alkali resistance; have high affinity; can be used to purify AAV virus particles or AAV virus vectors.
[0007] The present invention is achieved through the following technical solutions:
[0008] Two small peptide sequences for binding to multiple serotypes of adenovirus include a VX small peptide sequence and a D05 small peptide sequence, wherein the amino acid sequence of the VX small peptide sequence is shown in SEQ ID NO.1; and the amino acid sequence of the D05 small peptide sequence is shown in SEQ ID NO.2.
[0009] Preferably, the serotype adenovirus is any one of AAV2, AAV5 and AAV8.
[0010] The invention discloses an application of two small peptide sequences for binding to multiple serotypes of adenoviruses in the preparation of AAV affinity chromatography medium ligands.
[0011] An affinity chromatography medium ligand comprises the two small peptide sequences for binding to multiple serotypes of adenovirus.
[0012] The invention discloses an application of an affinity chromatography medium ligand in preparing purified AAV virus particles or AAV virus vector products.
[0013] An alkaline-resistant affinity chromatography medium ligand comprises the two small peptide sequences for binding to multiple serotypes of adenovirus.
[0014] Preferably, the affinity chromatography medium ligand is able to resist the action of 0.15N sodium hydroxide solution.
[0015] Compared with the prior art, the present invention has at least the following technical effects:
[0016] The present invention provides two small peptide sequences for binding to multiple serotypes of adenoviruses, including a VX small peptide sequence and a D05 small peptide sequence. The two small peptide sequences can be used to manufacture AAV affinity chromatography medium ligands; are used to bind to multiple different serotypes of adenoviruses; have strong alkali resistance; have high affinity; and can be used to purify AAV virus particles or AAV virus vectors. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 This is a schematic diagram of the conserved sequences of VP1, VP2, and VP3 proteins on the surface of AAV;
[0018] Figure 2 This is a schematic diagram of the expression results of VP3 immunogens of 10 different serotypes of AAV viruses, from AAV-1 to AAV-10;
[0019] Figure 3 This is a schematic diagram of the polypeptide structure of the small peptide in the technical solution of this application;
[0020] Figure 4 It is the AAV VP3 capsid protein, of which the dark orange is chain A;
[0021] Figure 5 Schematic diagram of the interaction between VP3 and D05-24;
[0022] Figure 6 Schematic diagram of the interaction between VP3 and VX-19. DETAILED DESCRIPTION
[0023] The embodiments of the present invention will be described in detail below in conjunction with examples. However, those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. The specific conditions not specified in the examples are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.
[0024] A technical solution of a specific implementation of the present invention is:
[0025] Theoretically, there are conserved surface sequences among AAV viral vectors of different serotypes, which makes it possible to screen small peptides with broad-spectrum binding activity.
[0026] like Figure 1 Shown is a schematic diagram of the conserved sequences of VP1, VP2, and VP3 proteins on the surface of AAV.
[0027] In the figure, the AAV surface VP3 protein contains conservative sequences such as GADGVGX1X2SGX3WHCDS, STRTWX4LPX5YNNH, STPWGYFDFNRFH, SPRDWQRLINN, FNIQVKEVT, CLEYFPSX6MLRTGNNF, etc. In theory, these regions can become broad-spectrum epitopes recognized by small peptides.
[0028] Among them, X1=N or S; X2=A or S; X3=N or D; X4=A or V; X5=T or S; X6=Q or K.
[0029] 1. Obtaining immunogens
[0030] The VP3 protein genes of 10 different serotypes of AAV viruses, such as AAV-1 to AAV-10, were synthesized with a polyhistidine tag (6x His tag) at the C-terminus and cloned into the NdeI-XhoI region of pET-30a(+). The genes were then transformed into the E. coli expression strain BL21(DE3) for expression.
[0031] like Figure 2 Shown is a schematic diagram of the expression results of VP3 immunogens of 10 different serotypes of AAV viruses, from AAV-1 to AAV-10.
[0032] Figure 2 Ten VP3 immunogens were prepared, but some of them were fragmented.
[0033] The AAV-1VP3 amino acid sequence is shown in SEQ ID NO.3;
[0034] The AAV-2VP3 amino acid sequence is shown in SEQ ID NO.4;
[0035] The AAV-3VP3 amino acid sequence is shown in SEQ ID NO.5;
[0036] The AAV-4VP3 amino acid sequence is shown in SEQ ID NO.6;
[0037] The AAV-5VP3 amino acid sequence is shown in SEQ ID NO.7;
[0038] The AAV-6VP3 amino acid sequence is shown in SEQ ID NO.8;
[0039] The AAV-7VP3 amino acid sequence is shown in SEQ ID NO.9;
[0040] The AAV-8VP3 amino acid sequence is shown in SEQ ID NO.10;
[0041] The AAV-9VP3 amino acid sequence is shown in SEQ ID NO.11;
[0042] The AAV-10VP3 amino acid sequence is shown in SEQ ID NO.12.
[0043] In order to improve the immune effect, purified AAV-2, AAV-5, AAV-8, and AAV-9 serotype virus vectors were purchased from Shanghai Heyuan Biotechnology and used as virus particle-like immunogens in subsequent alpaca immunization. The information of the four virus vectors is shown in Table 1 below.
[0044] Table 1
[0045] Immunogen name Titer (vg / mL) AAV-2 Virus Particles <![CDATA[1.64×10 13 ]]> AAV-5 Virus Particles <![CDATA[2.37×10 13 ]]> AAV-8 Virus Particles <![CDATA[2.13×10 13 ]]> AAV-9 Virus Particles <![CDATA[1.59×10 13 ]]>
[0046] 2. Immunize alpacas with immunogen to obtain immune serum
[0047] ①Immunization plan:
[0048] Take 50 μL of AAV-8 and dilute to 10 mL, then divide into 5 tubes, 2 mL / tube; take 50 μL each of AAV-2 / 5 / 9 and dilute to 2 mL respectively.
[0049] First shot: AAV-8 2mL
[0050] Second shot: AAV-8 2mL
[0051] The third injection: add 25 μL each of AAV-2 / 5 / 9 to 2 mL of AAV-8
[0052] Fourth injection: add 25 μL each of AAV2-2 / 5 / 9 to 2 mL of AAV-8
[0053] Fifth injection: 200ug each of VP3 protein of AAV-2 / 5 / 8 / 9
[0054] ②Immunization progress chart
[0055] Table 2
[0056] content Days (days) Serum collection amount / immunization dose Negative serum collection 0 2 mL of serum was collected before immunization Primary immunization 1 First shot, intramuscular injection Secondary Immunization 14 Second shot, intramuscular injection Three immunizations 28 The third shot, intramuscular injection Four immunizations 42 Fourth shot, intramuscular injection Serum collection and ELISA testing 49 Collect 2mL of serum for titer test Five immunizations 56 Fifth injection, intramuscular injection Serum collection and ELISA testing 63 Collect 2mL of serum for titer test
[0057] ③Construct immune library: Take B lymphocytes from alpaca blood, extract RNA from them and transcribe them into cDNA. Construct alpaca antibody gene library. Use the library and VP3 protein for alpaca nanoantibody screening (ELISA method).
[0058] ④ Obtain the nanoantibody sequence by sequencing, and synthesize the CDR3 amino acid sequence therein.
[0059] Sequence Listing
[0060]
[0061]
[0062]
[0063] The above sequences VX-19 and D05-24 are the small peptide sequences protected by the technical solution of this application.
[0064] VX-19 and D05-24 are codes given by the inventors themselves.
[0065] It refers to a small peptide of 25 amino acids in length screened from clone B11.
[0066] The above-mentioned VX-19 refers to a small peptide of 19 amino acids in length screened from clone V10;
[0067] The above-mentioned D05-24 refers to a small peptide of 24 amino acids in length screened out from clone D05.
[0068] In the content of this application document, the small peptide sequences protected by the technical scheme of this application are represented by VX-19 and D05-24.
[0069] 3. Use molecular docking to determine the theoretical binding site between the small peptide and VP3
[0070] VX-19 and D05-24 small peptides are the CDR3 regions of the VHH of the anti-AAV VP3 protein. Based on their sequences, AlphaFold2 was used to construct the peptide structures (e.g. Figure 3 shown).
[0071] Figure 3 In the figure, A is the structure diagram of the D05-24 small peptide polypeptide; B is the structure diagram of the VX-19 small peptide polypeptide.
[0072] The crystal structure 8FQ4 is a capsid protein assembled by the interaction of 60 AAV VP3s. Figure 4 The molecule (shown) was docked with two short peptides (using Rosetta software) to predict their interaction.
[0073] Docking revealed that D05-24 interacted with residues such as Asn710 and Asp716 of the VP3 protein;
[0074] VX-19 interacts with residues Asp556, Pro724, Asn704, Tyr701, and Tyr705 of the VP3 protein.
[0075] Table 3
[0076] VP3 D05-24 Tyr13-Asn710, Gly11-Asp716 VX-19 Ser10-Asp556, Ser13-Pro724, Asp16-Asn704, Tyr17-Tyr701, Tyr19-Tyr705
[0077] Docking diagram Figure 5 Shown is the interaction between VP3 and D05-24.
[0078] Docking diagram Figure 6 Shown is the interaction between VP3 and VX-19.
[0079] 4. Affinity of small peptides and AAV viral vectors
[0080] Octet Fortebio K2 and AAVX-biosensor were used to detect the affinity of small peptides. Dilution buffer: PSBT (1×PBS + 0.02% Tween 20)
[0081] Fixed objects: AAV2, AAV5, AAV8, AAV9 (4×10 11 vg / ml); Analytes: VX-19 (20 μM), D05-24 (20 μM). The test results are as follows:
[0082] Table 4
[0083] Fixtures VX-19KD (M) D05-24 KD(M) AAV2 (20 μM) <1.0E-12 <1.0E-12 AAV5 (20 μM) <1.0E-12 <1.0E-12 AAV8 (20 μM) <1.0E-12 <1.0E-12 AAV9 (20 μM) / /
[0084] The results in the above table show that the VX-19 peptide has strong binding activity with AAV-2, AAV-5, and AAV-8, but does not bind to AAV-9.
[0085] The D05-24 peptide has strong binding activity with AAV-2, AAV-5, and AAV-8, but does not bind to AAV-9.
[0086] 5. Alkali resistance of small peptides
[0087] The peptide was placed in 0.15N NaOH, 0.5N NaOH and 1N NaOH aqueous solutions for 30 minutes each, then the alkali solution was dialyzed away and the affinity was tested again.
[0088] Table 5
[0089]
[0090]
[0091] The above results show that the small peptide can resist the action of 0.15N NaOH and its affinity decreases to varying degrees in high concentration alkali solution.
[0092] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A small peptide for binding to multiple serotypes of adenovirus, characterized in that: The small peptide is a VX small peptide or a D05 small peptide, the amino acid sequence of the VX small peptide is shown in SEQ ID NO.1; the amino acid sequence of the D05 small peptide is shown in SEQ ID NO.
2.
2. Use of the small peptide for binding to multiple serotypes of adenovirus as claimed in claim 1 in the preparation of AAV affinity chromatography medium ligand.
3. An affinity chromatography medium ligand, characterized in that: The method comprises the small peptide for binding to adenovirus of multiple serotypes as claimed in claim 1.
4. Use of the affinity chromatography medium ligand as claimed in claim 3 in the preparation of purified AAV virus particles or AAV virus vector products.
5. An alkaline-resistant affinity chromatography medium ligand, characterized in that: The method comprises the small peptide for binding to adenovirus of multiple serotypes as claimed in claim 1.
